BeiGene, Ltd. American Depositary Shares
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Employees: 10,000
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $22.6M
4% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 74
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
2% less funds holding
Funds holding: 224 [Q3] → 219 (-5) [Q4]
23% less capital invested
Capital invested by funds: $10.4B [Q3] → $8.06B (-$2.37B) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 6 (-4) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ONC.
Financial journalist opinion
Based on 4 articles about ONC published over the past 30 days
